Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854416 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL20680182 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL20680545 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL2973089 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL2973085 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| Formic Acid SCHEMBL3459143 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL15106276 | 0.83 | PKM (0.53) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL15106278 | 0.83 | PKM (0.53) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL3892811 | 0.83 | PKM (0.53) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 | |
| SCHEMBL15106275 | 0.83 | PKM (0.53) | SMN1; SMN2PDK1ALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019020763-A1 | SEQUANAMYCIN MACROLIDES USEFUL IN THE TREATMENT OF TUBERCULOSIS | SANOFI (FR) | 2019-01-31 | — | — | WO | claimed |
| WO-2019020767-A1 | SEQUANAMYCIN MACROLIDES USEFUL IN THE TREATMENT OF TUBERCULOSIS | SANOFI (FR) | 2019-01-31 | — | — | WO | claimed |
| WO-2019020759-A1 | SEQUANAMYCIN MACROLIDES USEFUL IN THE TREATMENT OF TUBERCULOSIS | SANOFI (FR) | 2019-01-31 | — | — | WO | claimed |
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | claimed |
| WO-2010027564-A2 | AMIDO ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-03-11 | — | — | WO | claimed |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | SCHMITZ FRANZ ULRICH | 2010-03-11 | — | — | US | claimed |
| WO-2009147211-A1 | NEW COMPOUNDS V | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | claimed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-1912972-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2008-04-23 | — | — | EP | claimed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | claimed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | SMN1; SMN2 1880/4885PDK1 362/4885ALDH1A1 1685/4885 |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | SLC18A2, SLC6A2, SLC18A1 | SMN1; SMN2 634/4885PDK1 489/4885ALDH1A1 495/4885 |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, OAT, MAVS | SMN1; SMN2 126/4885PDK1 4863/4885ALDH1A1 4853/4885 |
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | SMN1; SMN2 4479/4885PDK1 393/4885ALDH1A1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.